Professor of Biology and Executive Director of the Institute for the Advancement of Community Health (IACH)
Eli Hestermann is the founding executive director of the Institute for the Advancement of Community Health at Furman University and is responsible for aligning its programs and initiatives with the strategic visions of both Furman University and Prisma Health, where he also serves as executive director of Pre-professional Studies. Hestermann has been a biology professor at Furman since 2003, with expertise in cell biology, pharmacology, toxicology and endocrinology and research interests in regulation of gene expression in cancer and environmental health. He has been recognized as an outstanding undergraduate research mentor by both the South Carolina IdEA Networks of Biomedical Research Excellence and the Howard Hughes Medical Institute. He holds a B.S. in biology from Purdue University, a Ph.D. in biological oceanography from Massachusetts Institute of Technology and Woods Hole Oceanographic Institution, and trained in cancer pharmacology at Dana Farber Cancer Institute and Harvard Medical School.
- Ph.D., Massachusetts Institute of Technology and Woods Hole Oceanographic Institution
- B.S., Purdue University
Dr. Eli Hestermann's research focuses on regulation of gene expression by hormones and toxicants in a variety of cell types and animals, from breast cancer to endometriosis to trout brain. He uses molecular and biochemical techniques, including tissue culture, real-time PCR, chromatin immunoprecipitation, receptor ligand binding, immunoblots, immunofluorescence, flow cytometry, high throughput sequencing, bioinformatics, and DNA cloning and sequencing. His students have presented at regional, national and international conferences, and include best poster, best oral presentation, and best student paper awards received in competitions involving graduate students. He collaborates with several colleagues in biology and chemistry on campus, and with others at Greenville Memorial Hospital, Woods Hole Oceanographic Institution, Boston University, University of South Florida and University of the Pacific. Future plans include application of bioinformatics approaches to conservation biology.
- *Denotes undergraduate coauthor
- Yang, X., S. Solomon, L.R. Fraser*, A.F. Trombino, D. Liu, G.E. Sonenshein, E.V. Hestermann, D.H. Sherr (2008). Constitutive Regulation of CYP1B1 by the aryl hydrocarbon heceptor (AhR) in pre-malignant and malignant mammary tissue. J. Cell. Biochem. 104:402-417.
- Hahn, M.E. and E.V. Hestermann (2008). "Molecular Mechanisms of Toxicity" in The Toxicology Of Fishes, Richard T. DiGiulio and David E. Hinton, eds. CRC Press.
- Yang, X., D. Liu, T.J. Murray, G.C. Mitchell*, E.V. Hestermann, S.I. Karchner, R.R Merson, M.E. Hahn, D.H. Sherr (2005). The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene 24:7869-7881.
- Carroll, J. S. X. S. Liu, A.S. Brodsky, W. Li, C. A. Meyer, A. J. Szary, J. Eeckhoute, W. Shao, E. V. Hestermann, T. R. Geistlinger, E. A. Fox, P. A. Silver, M. Brown. (2005). Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33-43.
- Hestermann, E. V. and M. Brown (2003). Agonist and Chemopreventative Ligands Induce Differential Transcriptional Cofactor Recruitment by Aryl Hydrocarbon Receptor. Molecular and Cellular Biology 23 (21):7920-5.
- Hestermann, E. V., J. J. Stegeman, and M. E. Hahn (2000). Relative Contributions of Affinity and Intrinsic Efficacy to Aryl Hydrocarbon Receptor Ligand Potency. Toxicology and Applied Pharmacology. 168:160-172.
- S. C. Amaya, R. F. Savaris, C. J. Filipovic, J. D. Wise*, E. Hestermann, S. L. Young, B. A. Lessey (in press). Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models. Reproductive Sciences.